Background
Cigarette smoking is the most important risk factor for Chronic Obstructive Pulmonary Disease (COPD) [
1]. However, only a proportion of all smokers, about 15-20%, will actually develop COPD, the so-called `susceptible’ smokers. It is still unclear which factors determine why these individuals are more sensitive to the detrimental effects of cigarette smoking compared with `non-susceptible’ smokers.
To better understand how cigarette smoking leads to irreversible lung damage and chronic airflow obstruction, knowledge of the initial responses to cigarette smoking might be very useful. Several studies investigated the acute inflammatory and oxidative stress responses to cigarette smoking in animal and
in vitro models, yet only a few studies investigated these responses in humans [
2]. These studies focused generally on COPD patients and `healthy smokers’ without airway obstruction. However, aging and the cumulative amount of pack-years smoking may lead to changes in the airways and lung parenchyma in both groups, likely affecting their response to cigarette smoking. Particularly in COPD, the structural changes in the lung may lead to a different response to smoking. For this reason, it might be hypothesized that the very first responses to cigarette smoking in healthy young individuals with a low number of pack-years is an ideal model to investigate the induction and early progression towards COPD.
Several family studies have provided evidence that a genetic predisposition is involved in the smoking-related development of COPD. Silverman et al. showed that smoking or ex-smoking in first degree relatives of early-onset COPD probands associates significantly with lower forced expiratory volume in one second (FEV
1) values compared to relatives of control subjects [
3]. Several other studies have demonstrated that the combination of smoking and familial clustering of COPD strongly associates with a higher risk for COPD [
4]-[
6]. Although a history of familial COPD may help to identify smokers who are susceptible to develop COPD themselves, a more discriminative biomarker would be welcome in the field of preventive medicine. Additionally, elucidating the smoking-induced pathogenesis of COPD in susceptible individuals may ultimately lead to the identification of new drug targets.
The aim of this study was to identify early biomarkers of COPD susceptibility by investigating acute responses to cigarette smoke in young (18-40 years) individuals susceptible and non-susceptible to develop COPD, based on a high prevalence or absence of COPD in smoking relatives. All subjects smoked three cigarettes in one hour. Before and after smoking, inflammatory markers were determined in peripheral blood and bronchial biopsies. We hypothesized that susceptible individuals exhibit a different systemic and local inflammatory response compared to non-susceptible individuals. In addition, we investigated the acute response to cigarette smoking in older (ex) smokers with and without COPD, to assess if responses to cigarette smoking change after many years of smoking.
Discussion
This is the first human study using an acute smoking design in a population of young and old individuals being susceptible or non-susceptible to develop COPD. The focus of this study was on the comparison of the acute response to cigarette smoking in young individuals, older subjects were investigated to assess if responses change after many years of smoking. We demonstrated that susceptibility to develop COPD at young age associates with an enhanced innate immune response to cigarette smoking in peripheral blood when compared with non-susceptible individuals, suggesting that a systemic inflammatory component is involved during the induction of COPD.
Our most important finding is that peripheral blood neutrophil activation markers were differentially expressed after smoking between young susceptible and young non-susceptible subjects. Previous human studies have shown that the number of peripheral blood neutrophils increases after acute smoking [
2], a finding that we confirmed, i.e. neutrophils (CD16
+ granulocytes) significantly increased in both the susceptible and non-susceptible group (Figure
3). However, the activation of neutrophils is a well-described multi-step process, generally starting with priming (pre-activation) caused by chemotaxins or cytokines, leading to upregulation of integrins and adhesion molecules (e.g. CD11b, ICAM-1) [
11],[
12]. Additionally, primed neutrophils can be recognized by MoPhab antibodies A17 and A27 since they bind FcγRII (CD32) only in the context of primed cells and exquisitely capable to detect primed cells in the circulation [
10],[
13]. We found that acute smoking significantly increased median A17 and A27 expression only in the group of young susceptible subjects (Table
2, Figure
2). This effect was further confirmed by regression analyses, showing that this increase was independently of age, smoking status and marker expression at baseline. In contrast, receptors involved in adhesion and migration tended to decrease after smoking, which was significant for ICAM-1 and CD182/CXCR2 markers in susceptible subjects and for CD181/CXCR1 and CD182/CXCR2 in non-susceptible subjects. Taken together these data suggest that circulating neutrophils become more activated immediately after smoking, and particularly so in young susceptible subjects.
The underlying mechanisms are complex. Some
in vitro studies have shown that circulating neutrophils of smokers are pre-activated or primed compared with never-smokers and have a higher capacity to migrate towards chemotactic stimuli, or are more responsive to activating agents [
14],[
15]. We did not investigate chemotactic characteristics of neutrophils, however, our data are pointing at a mechanism by which neutrophils are more easily primed in young susceptible individuals. This may contribute to a higher influx of neutrophils into the airways, leading to more intense inflammation and tissue damage. The trend we found in reduced expression of ICAM-1 in young susceptible individuals supports this hypothesis. Neutrophils with upregulated expression of adhesion molecules may already have left the circulation infiltrating the lung tissue. This concept has also been proposed for eosinophils in allergic asthma by Johansson et al [
16]. Interestingly, we demonstrated that a higher increase of ICAM-1 expression on circulating neutrophils upon smoking was associated with a higher increase of bronchial biopsy neutrophils. In the same model, being susceptible to develop COPD and current smoking were independent predictors of neutrophil influx after smoking, indicating that the influx of cells is higher in susceptible individuals who smoke. However, no significant associations were found between bronchial cell counts and the other neutrophil activation markers. This lack in association may be due to the fact that blood and bronchial biopsies were collected at different time points. Nevertheless, it is encouraging that our methods identified subtle alterations in the activation state of circulating neutrophils associated with changes in neutrophil numbers in the airways.
Blood eosinophil numbers decreased after smoking both in young susceptible and non-susceptible subjects, a finding in accordance with our previous study on acute smoking effects in intermittent smokers [
17]. Another study in four young healthy women demonstrated a decreased number of eosinophils two hours after smoking of 12 cigarettes [
18]. Interestingly, eosinophil numbers also significantly decreased after smoking in COPD patients and healthy controls. The underlying mechanism is yet to be defined, but a similar situation is found upon systemic LPS challenge in man [
19]. Apparently, eosinophil homing signals are generated by innate immune signals such as DAMPs (acute smoking) and PAMPs (LPS). Our study did not show associations between smoking-induced changes in eosinophil numbers and cytokine concentrations in blood, suggesting that remaining eosinophils were not responsive to the cytokines with respect to homing of the cells. Another explanation might be that eosinophils migrated from the circulation into the lung tissue. However, we did not find an associated rise in eosinophil numbers in bronchial biopsies after smoking. A final explanation is that toxic substances in cigarette smoke cause apoptosis [
20], a phenomenon we did not investigate specifically. Interestingly, susceptible subjects had a deeper fall in eosinophils than non-susceptible subjects in both the young and old population, although this finding did not remain significant in multiple regression analysis. Apparently, the eosinophilic response to cigarette smoke is not contributing to susceptibility, in contrast to the neutrophilic response.
Next we investigated whether the differences in responses to cigarette smoke between young susceptible and non-susceptible subjects were also present between COPD patients and healthy controls. Here we found no differences in expression of neutrophil activation markers in peripheral blood after smoking, which may be due to the fact that they were older and had more pack-years. It is known that age and prolonged smoking increases systemic inflammation [
21]. Further, several studies have demonstrated that neutrophils are more activated in COPD patients [
22], and this may have obscured a relatively subtle response on recent smoking exposure. However, basal levels of expression markers in both our old groups did not differ, thus a different explanation is required. There, we postulate that the inflammatory response to cigarette smoking after long-term smoking has faded out or has been switched into a more persistent inflammatory response, minimizing the ability to detect subtle changes in neutrophil activation.
Smoking of three cigarettes did not affect inflammatory cell counts in bronchial biopsies 24 hours later. This contrasts with findings in animal models, where acute smoking results in an influx of inflammatory cells in lung tissue 6-24 hours later [
23]-[
25]. The time point of 24 hours after smoking was chosen based on animal studies given the lack of data in men [
2],[
7]. It may well be that the response to cigarette smoking in human occurs early after smoking, or that animals were exposed to relatively much higher levels of cigarette smoke. Smoking in human has been shown to increase neutrophils in sputum [
17], bronchoalveolar lavage fluid (BALF) [
26] and lung tissue using nuclear imaging techniques [
27]. Possibly, the main effects of smoking do not take place in the large airways, but at other lung regions like peripheral airways and lung parenchyma. Clearly, our negative biopsy findings can be explained in a number of ways: collecting biopsies too late after smoking, smoking of too few cigarettes, or investigating the wrong lung compartment. Future human studies must take these considerations into account.
The strengths of our study are that we investigated young individuals with normal lung function who are either susceptible or not susceptible to develop COPD and we used a disease-specific challenge to find biomarkers of COPD susceptibility. There are some limitations as well. First, we defined COPD susceptibility on familial history of COPD only; no lung function measurements were performed to verify COPD in family members. However, family history of COPD is a strong risk factor of COPD [
5] and we maintained a strict inclusion algorithm [
7]. Second, we used exhaled CO to verify smoking abstinence before the acute smoking procedure, yet this is only reliable within 6 hours of smoking cessation. Third, the young susceptible group smoked a higher number of pack-years compared with the susceptible group. Fourth, the number of participants was relatively low, especially in the young susceptible and the COPD group. Additionally, we lost some data because 21% of the subjects did not complete the two bronchoscopies. However, our significant findings are relevant as they were found in spite of the low sample size of this study.
In conclusion, we found that COPD susceptibility at young age associates with an increased activation of peripheral neutrophils after cigarette smoking. This increased innate immune response was not found at old age, likely because the inflammatory response to cigarette smoking has faded out or has been switched into a more persistent inflammatory response as a result of long-term smoking or aging. Our data emphasizes that systemic inflammation contributes likely to the early induction phase of COPD.
Authors’ contributions
SH: Contributed to data collection, data analysis, interpretation of data, writing and editing of the manuscript. WT: Contributed to the study concept and design, data analysis, interpretation of data, writing and editing of the manuscript. LK: Contributed to the study concept and design, interpretation of data, writing and editing of the manuscript. ALTL: Contributed to interpretation of data, writing and editing of the manuscript. JWL: Contributed to the study concept and design, interpretation of data, writing and editing of the manuscript. HMB: Contributed to the data analysis, interpretation of data, writing and editing of the manuscript. AO: Contributed to the interpretation of data, writing and editing of the manuscript. DP: Contributed to the study concept and design, data analysis, interpretation of data, writing and editing of the manuscript. NH: Contributed to the study concept and design, data analysis, interpretation of data, writing and editing of the manuscript. All authors read and approved the final manuscript.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Competing interests
This research was done in the framework of the Top Institute Pharma project T1-108 with partners University Medical Center Groningen (UMCG), University of Groningen (RUG), GRIAC research institute Groningen, University Medical Center Utrecht (UMCU), Nycomed BV, GlaxoSmithKline, and Foundation TI Pharma.
SH, LK, ALTL, HMB, and AO declare that they have no competing interests. The university of Groningen, received fees for consultancies of WT from Pzizer, GlaxoSmithKline, Chiesi, Roche Diagnostics/Ventana, and Dutch Asthma Fund. JWL received consultancies from GlaxoSmithKline and Chiesi. The University of Groningen, received fees for consultancies of DP from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Takeda, Nycomed, and TEVA, and grants from AstraZeneca and Chiesi. NTH received grants from GlaxoSmithKline, Boehringer Ingelheim, Nycomed, and Chiesi.